Colorcon acquires business of Pharmaceutical Coatings

Colorcon, Inc. today announced the acquisition of the business of Pharmaceutical Coatings Pvt. Ltd. (India) which includes the company's full product portfolio, plus a new facility in Goa that is currently under construction.

The addition of the film coating products from this acquisition complement Colorcon's existing wide range of high-quality, one-step, tablet film coatings for pharmaceutical solid oral dose development.

Tabcoat TC®, one of the newly acquired products, is widely recognized in the Asia/Pacific market.  It is available as an organic, hydro-alcoholic, or aqueous solvent system which can be adjusted according to the needs of the customers, and the nature of the active ingredient in the formulation.  The addition of this product also augments Colorcon's offering for herbal / vitamin / nutraceutical formulation options for its regional customers.  

According to Jean-Claude Deneuville, President of Colorcon, Inc., "We are excited about this opportunity to expand our film coating offering.  The acquisition broadens and strengthens our ability to respond to the specific needs of companies in the fast growing Asia/Pacific region.  We will ensure the same high quality level of expertise, technical service, production and logistics support for these products that our customers have come to expect from Colorcon."  

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Tertiary lymphoid structures linked to improved outcomes in liver cancer patients